AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

APO Importer 02:08 - 18 August 2024

AstraZeneca

Today marks an important step in turning the corner on the pandemic and getting things back to normal.Following the positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil, which showed the vaccine was highly effective in preventing COVID-19, we are confident that our united response, across the scientific community,industry, organisations, and governments, will make significant inroads in curbing the COVID-19 pandemicthat has continued to claim...

Barbara Nel Country President African Cluster: South Africa, Sub Saharan Africa, French Speaking Africa

Full AstraZeneca Regulatory News Service News Release available here (https://bit.ly/339VrKS).

Distributed by APO Group on behalf of AstraZeneca.

About AstraZeneca: AstraZeneca (www.AstraZeneca.com) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.AstraZeneca.com and follow the Company on LinkedIn @AstraZeneca .

Media files